Efficacy of topical Linum usitatissimum L. (flaxseed) oil in knee osteoarthritis: A double-blind, randomized, placebo-controlled clinical trial by Mosavat, Seyed Hamdollah et al.
Research Article
Ceftriaxone, a Beta-Lactam Antibiotic,
Modulates Apoptosis Pathways and Oxidative Stress
in a Rat Model of Neuropathic Pain
Bahareh Amin,1 Valiollah Hajhashemi,2 Khalil Abnous,3 and Hossein Hosseinzadeh4
1 Department of Pharmacology and Physiology, Faculty of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran
2Department of Pharmacology, Pharmaceutical Sciences Research Center, School of Pharmacy,
Isfahan University of Medical Sciences, Isfahan, Iran
3Department of Biotechnology, Pharmaceutical Research Center, School of Pharmacy,
Mashhad University of Medical Sciences, Mashhad, Iran
4 Pharmaceutical Research Center, Pharmacodynamy and Toxicology Department, School of Pharmacy,
Mashhad University of Medical Sciences, P.O. Box 1365-91775, Vakilabad Boulevard, Mashhad, Iran
Correspondence should be addressed to Hossein Hosseinzadeh; hosseinzadehh@mums.ac.ir
Received 23 February 2014; Revised 13 May 2014; Accepted 13 May 2014; Published 16 June 2014
Academic Editor: Livio Luongo
Copyright © 2014 Bahareh Amin et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Purpose. In our previous study, ceftriaxone, a beta-lactam antibiotic, elicited antinociceptive effects in the chronic constriction
injury (CCI) of neuropathic pain. In this study, we assessed apoptosis and oxidative stress in the spinal cord of neuropathic rats
treated with ceftriaxone. Methods. 45 male Wistar rats were divided as na¨ıve, sham, normal saline-treated CCI rats, and CCI
animals treated with the effective dose of ceftriaxone. Involvement of Bax, Bcl2, and caspases 3 and 9, important contributors
of programmed cell death (apoptosis), was determined using western blotting at days 3 and 7. The markers of oxidative stress
including malondialdehyde (MDA) and reduced glutathione (GSH) were measured on days 3 and 7. Results. Increased Bax/Bcl2
ratio and cleaved active forms of caspases 3 and 9 were observed in the spinal cord of CCI rats on day 3. Ceftriaxone attenuated
the increased levels of Bax and cleaved forms of caspases 3 and 9, while it increased Bcl2 levels. Bax and active forms of caspases
declined by day 7. Consequently, comparison among groups showed no difference at this time. CCI enhanced MDA and decreased
GSH on days 3 and 7, while ceftriaxone protected against the CCI-induced oxidative stress. Conclusion. Our results suggest that
ceftriaxone, an upregulator/activator of GLT1, could concomitantly reduce oxidative stress and apoptosis and producing its new
analogs lacking antimicrobial activity may represent a novel approach for neuropathic pain treatment.
1. Introduction
Nerve injury induced chronic pain, often referred as neuro-
pathic pain, is caused by a primary lesion in both central
and more frequently peripheral nervous systems and is a
challenging condition to treat [1]. Molecular mechanisms
involved in this pathological chronic pain syndrome have
currently been an area of much interest.
Excitotoxicity via elevated excitatory neurotransmitters
(glutamate and aspartate) has been associated in different
kinds of pain such as neuropathic pain [2]. In recent years,
different studies have pointed out the role of apoptosis in
neuropathic pain. In a study by de Novellis et al., apoptotic
pathways were activated in rat spinal cord of sciatic nerve
chronic constriction injury (CCI), and the early overexpres-
sion of proapoptotic genes and morphological changes in
dorsal horn were prevented by blockade of glutamate mGlu5
receptors [3]. Afrazi et al. reported that diabetes-induced
hyperalgesia in rats was attenuated by neurosteroid, allopreg-
nanolone through inhibiting caspase-3 and decreased ratio
of Bax to Bcl2 [4]. Moreover, numerous studies revealed that
oxidative stress plays an important role in neuropathic pain
[5, 6]. Considering that extra levels of glutamate lead to a
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number of deleterious effects, including excessive activation
of central glutamate receptors, impairment in buffering of
calcium, production of free radicals by lipid peroxidation,
secondary excitotoxicity, and cell death following neuro-
pathic pain maintaining low extracellular glutamate, is very
important [7, 8]. Glutamate hemostasis is performed via
high affinity transporters in which GLT 1 is the predominant
subtype and accounts for clearance of the bulk of released glu-
tamate. Downregulation of glutamate transporters is thought
to be very important in various experimental neuropathic
painmodels [9]. Recently, ceftriaxone a third generation beta-
lactam antibiotic has been discovered to have neuroprotective
effects in various in vitro and in vivo studies [10, 11]. The pre-
cise primary molecular mechanism of ceftriaxone is thought
to be mediated by the increased expression and activation
of GLT1 in the CNS [11–13]. We and others have previously
reported that ceftriaxone could attenuate pain behaviors of
rats subjected to the CCI model of neuropathic pain [14,
15]. If apoptosis process and oxidative stress were linked
to excitotoxicity, then treatment with ceftriaxone would be
predicted to reverse spinal cord protein changes involved in
the apoptosis and oxidative stress following CCI.
Therefore, the aim of the present study was to determine
time course of changes in the spinal cord levels of apoptosis-
related proteins. Bax, a promoting factor, Bcl2, which can
prevent apoptosis, caspase-9, the initiator caspase for the
activation of downstream caspases, and caspase-3, a factor
in downstream of several apoptotic pathways [16], were
analyzed with western blotting on days 3 and 7 after CCI. To
study whether treatment with ceftriaxone was able to show
antioxidant activity, we assessed spinal cord levels of MDA,
the last product of lipid peroxidation [17] and glutathione,
the major sulfhydryl (-SH) antioxidant, and enzyme cofactor
[18], in 3 and 7 days in CCI rats.
2. Materials and Methods
2.1. Animals. Adult male Wistar strain rats weighing 220–
270 g at the time of surgery were used in this experiment
and randomly gathered from the animal room of the School
of Pharmacy, Mashhad University of Medical Sciences, Iran.
The animals were housed under standard environmental
conditions (12-12 h light/dark cycle at 22∘C). Rat chow and tap
water were available ad libitum. The experimental protocol
was approved byMashhadUniversity ofMedical Sciences and
performed in accordance with the Internationally Accepted
Principles for Laboratory Animal Use and Care [19].
2.2. Drugs and Solutions. Ceftriaxone (Jaber Ebne Hayyan
Pharmaceutical Co., Tehran, Iran) was dissolved in normal
saline solution (0.9% NaCl) and intraperitoneally injected at
the dose of 200mg/kg. Ceftriaxone administration started
when CCI was induced and continued for 7 consecutive
days. Ketamine and xylazine (Alfasan Pharmaceutical Co.,
Woerden, Holland) were intraperitoneally injected at doses
of 64 and 1.6mg/kg, respectively.
2.3. CCI Surgery of Sciatic Nerve. At first, rats were anaes-
thetized with a cocktail of ketamine and xylazine. Mononeu-
ropathy was induced by performing chronic constriction
injurymodel on the left sciatic nerve of animals in accordance
with the method of Bennet and Xie [20]. After the incision of
the skin, the sciatic nerve was exposed and four ligatures of
4-0 gauge chromic catgut were tied loosely with an interval
of 1mm, until a slight twitching was observed in the expected
hind paw. Finally, muscle and skin were separately sutured
with 4-0 silk catgut and animals were placed in a warm
condition until recovery. Rats in the sham group had their
sciatic nerve exposed but not ligated.
2.4. Study Protocol. Based on our previous study, CCI led to a
significant development of mechanical allodynia (4.3 ± 0.6 g
versus 53 ± 6.7 g) and cold allodynia (73.3 ± 8.4% versus 8 ±
4.9%) on day 3 in comparison to sham group, as revealed by
von Frey hairs and acetone drop, respectively. Pain behaviors
progressively increased during the study on days 5 and 7. In
that study, mechanical and cold allodynia were significantly
attenuated by the dose of 200mg/kg of ceftriaxone on days 3
and 7 [14]. Accordingly the effective antinociceptive dose of
ceftriaxone (200mg/kg) was chosen in this study.
In the present study, to examine the time course of
changes in apoptosis-related proteins and oxidative stress
markers (MDA andGSH) in the spinal cord of CCI rats, three
animals from each group were harvested on postoperative
day 3 or day 7 after the behavioral tests. Hence, 54 rats
were randomly assigned into the following groups. (1, 2) The
animals were subjected to CCI surgery, treated with normal
saline (NS) at a dose of 1mL/kg, and killed on day 3 or
day 7 for evaluation of apoptotic factors (𝑛 = 3). (3, 4)
In sham group, the animals underwent a similar surgery
except that sciatic nerves were not ligated and treatedwith the
normal saline and killed on day 3 or day 7 for evaluation of
apoptotic factors (𝑛 = 3). (5, 6) CCI animals were treatedwith
ceftriaxone (200mg/kg, administered at a dose of 1mL/kg)
for seven days and killed on day 3 or day 7 for evaluation of
apoptotic factors (𝑛 = 3). (7, 8)The CCI animals were treated
with NS and killed on day 3 or day 7 for evaluation of MDA
(𝑛 = 3) and GSH (𝑛 = 3). (9, 10) Sham-operated animals
were killed on day 3 or day 7 for evaluation of MDA (𝑛 = 3)
and GSH (𝑛 = 3). (11, 12) CCI animals were treated with
ceftriaxone (200mg/kg) for seven days and killed on day 3
or day 7 for evaluation of MDA (𝑛 = 3) and GSH (𝑛 = 3). (13)
Na¨ıve animals were killed for evaluation of apoptotic factors
(𝑛 = 3), MDA (𝑛 = 3), and GSH (𝑛 = 3) contents.
For the protein extraction, the lumbar spinal cord was
rapidly ejected from the vertebral columnusing a saline-filled
syringe and then separated on dry ice. Lumbar (L4 and L5)
segments were excised to measure apoptotic and oxidative
stress markers considering that these segments are the major
contributor to the sciatic nerve [19].
2.5. Western Blotting. At the time of experiment, samples
were homogenized in the lysis buffer containing 50mM
Tris-HCl (pH: 7.4), 2mM EDTA, 2mM EGTA, 10mM
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NaF, 1mM sodium orthovanadate (Na3VO4), 10mM 𝛽-
glycerophosphate, 0.2% W/V sodium deoxycholate, 1mM
phenylmethylsulfonyl fluoride (PMSF), and complete pro-
tease inhibitor cocktail (Roche, Mannheim, Germany). The
homogenate was sonicated on ice with three 10 sec bursts
at high intensity with a 10 sec cooling period between each
burst. The samples were centrifuged at 10,000 g for 10min at
4∘C. After determining protein content by Bradford assay kit
and adjusting the protein content [20], each adjusted sample
was mixed 1 : 1 v : v with 2x SDS blue buffer, boiled, aliquoted,
and kept in the −80∘C freezer.
100 micrograms of each protein extracts was separated
on a 12% sodium dodecyl sulfate-polyacrylamide gel (SDS-
PAGE) by electrophoresis and transferred onto polyvinyli-
dene fluoride (PVDF) membranes. Then, blots were blocked
with 5% skim milk in TBST (20mM Tris-HCl pH 7.6,
137mM NaCl, and 0.05% Tween-20) at 4∘C overnight.
Mouse monoclonal anticaspase-9 (cell signaling number
9508, 1 : 1000), rabbit polyclonal anticaspase-3 (cell signal-
ing number 9665, 1 : 1000), rabbit polyclonal anti-Bax (cell
signaling number 2772, 1 : 1000), rabbit polyclonal anti-Bcl2
(cell signaling number 2870, 1 : 1000), and rabbit polyclonal
anti-𝛽-actin antibodies (cell signaling number 4967, 1 : 1000)
were used as a primary antibody with incubation time of
about 1-2 hours at room temperature, washing three times
with TBST and 1-hour incubation by rabbit horseradish
peroxidase-conjugate anti-rabbit IgG (cell signaling number
7074, 1 : 2000) or anti-mouse IgG (cell signaling number 7076,
1 : 2000). Enhanced chemiluminescence (Pierce) was used
to visualize the peroxidase-coated bands and Alliance 4.7
Gel Doc (UK). Densitometric analysis for protein bands was
performed using UVtec software (UK). The protein levels
were normalized against 𝛽-actin intensity.
2.6. Measurement of MDA Levels in the Spinal Cord of
Animals. Estimation of lipid peroxidation was performed
by measuring the thiobarbituric acid reactive substances as
described previously [21]. At the time of experiment, each
sample was weighed and homogenized in 1.15% potassium
chloride solution. Then, 3mL phosphoric acid (1%) and
1mL TBA (0.6%) were added to 0.5mL of homogenate in
a centrifuge tube and the mixture was heated for 45min
in a boiling water bath. After cooling, 4mL n-butanol was
added to the mixture and vortex mixed for 1min followed by
centrifugation at 3000 rpm for 15 minutes. The organic layer
was transferred to a fresh tube and the absorbance of pink
colored product was read at 532 nm. A set of MDA standards
was freshly prepared and the standard curve was constructed.
The results were expressed as the nmol of malondialdehyde
formed per mg of protein.
2.7. Measurement of GSH Levels in the Spinal Cord of Animals.
Total SH groups belonging to GSH were measured using
DTNB (2,2󸀠-dinitro-5,5󸀠-dithiodibenzoic acid) as the reagent.
This reagent reacts with the SH groups to produce a yellow
colored complex with a peak absorbance at 412 nm. Briefly,
a 10% tissue homogenate in buffer phosphate 7.4 was mixed
with an equal volume of 10% trichloroacetic acid (TCA) and
vortexed.The contents were then centrifuged at 5000 rpm for
10min. Subsequently 500𝜇L of supernatant was mixed with
a reaction mixture containing 2.5mL 0.1M phosphate buffer
(pH 8.4) and 0.5mL DTNB. Within 10min, the absorbance
was measured at 412 nm using a spectrophotometer. A set
of GSH standards was freshly prepared using commer-
cially available standard GSH (Sigma Chemicals, USA) and
the standard curve was constructed. Levels of GSH were
expressed as nmol/mg protein [22].
2.8. Statistics. Data were expressed as means ± SEM and
statistically analyzed by one-wayANOVA followed byTukey’s
post hoc tests, using SPSS version 13. A 𝑃 value of < 0.05 was
considered to be significant.
3. Results
3.1. Bax and Bcl2 Protein Levels. To analyze the amount
of the apoptotic proteins, a relative protein ratio to na¨ıve
animals was used. The results of western blotting analysis
indicated that lumbar spinal cord levels of the proapoptotic
protein, Bax increased within 3 days following sciatic nerve
CCI (control group), as compared to naı¨ve and sham groups,
while a slight but not significant decrease in the level
of antiapoptotic protein, Bcl2 was observed (Figure 1(a)).
Therefore, a significantly higher level of Bax/Bcl2 ratio was
obtained in the spinal cord of CCI animals in comparison
to naı¨ve and sham groups (𝑃 < 0.05) on day 3 after surgery
(Figure 1(b)). Whereas, there was no significant difference in
the levels of proteins between sham and na¨ıve animals treated
with ceftriaxone. In NS-CCI animals, protein levels of Bax
decreased andBcl2 increased on day 7 afterCCI. Accordingly,
there was no significant difference between Bax/Bcl2 ratio of
control group and that of sham and na¨ıve groups (Figures 1(c)
and 1(d)). CCI animals treated with 200mg/kg of ceftriaxone
(once daily, for 7 days) showed a significant increase in the
levels of antiapoptotic protein, Bcl2, and decreased contents
of Bax protein on day 3 after CCI, resulting in a significant
reduction in the Bax/Bcl2 ratio as compared to control group
(𝑃 < 0.05). No significant difference was observed in the
Bax/Bcl2 ratio between ceftriaxone treated animals and that
of control group on day 7 (Figure 1).
3.2. Caspase-9 Protein Levels. Our data showed that therewas
no significant difference in the levels of procaspase-9 protein
between sham and na¨ıve animals treated with ceftriaxone.
The expression of procaspase-9 increased on day 3 after CCI
when compared to that of the sham and na¨ıve groups (𝑃 <
0.01). A significant increase in the activated cleaved forms
of 37 kDa and specially 35 kDa species was observed 3 days
after the CCI as compared to that detected in the sham and
na¨ıve groups (𝑃 < 0.01) (Figures 2(a) and 2(b)). In CCI rats
who received 200mg/kg ceftriaxone (once daily, for 7 days)
contents of procaspase-9 (𝑃 < 0.05) as well as activated forms
(𝑃 < 0.01) decreased after 3 days of sciatic nerve injury
(Figures 2(a) and 2(b)).
Levels of procaspase-9 decreased from day 3 to day 7 after
surgery in normal saline CCI animals and activate cleaved
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Figure 1: Effect of ceftriaxone on the spinal cord protein levels of Bax (21 kDa) and Bcl2 (26 kDa) and relative density of Bax/Bcl2, following
western immunoblotting on days 3 (a and b, resp.) and 7 (c and d, resp.) after CCI. Administration of ceftriaxone (Cef 200mg/kg, i.p.) started
when CCI was induced and continued for 7 successive days. The semiquantitative analysis of protein levels was carried out by the “Gel Doc
2000 UV System” (Alliance 4.7). Each lane was loaded with 100𝜇g of proteins. 𝛽-actin is the loading protein control. Data are mean ± SEM
(𝑛 = 3/group). One-way ANOVA followed by Tukey’s post hoc test was used for multiple comparisons. #𝑃 < 0.05 difference between CCI-NS
and sham/naive groups. ∗𝑃 < 0.05 CCI-Cef versus NS-CCI group (control).
forms of caspase-9 were no longer detected by day 7. As a
result, no significant difference was observed among groups
at this time (Figures 2(c) and 2(d)).
3.3. Caspase-3 Protein Levels. On day 3 after surgery,
procaspase-3 protein levels increased in the spinal cord of
normal saline-treated CCI animals (control group), although
not to a significant extent. Cleaved formof the protein (17 kD)
was significantly increased in control group as compared
to naı¨ve and sham groups (𝑃 < 0.05) (Figures 3(a) and
3(b)). Despite the fact that there is no significant difference
between the relative density of procaspase-3 in CCI rats
and ceftriaxone treated animals, activated forms of caspase-
3 were significantly attenuated by ceftriaxone (200mg/kg), as
compared toCCINS-treated rats (𝑃 < 0.05) (Figures 3(a) and
3(b)). Activated cleaved forms of caspase-3 were no longer
detected by day 7. Accordingly, no significant difference was
observed among groups at this time (Figures 3(c) and 3(d)).
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Figure 2: Effect of ceftriaxone on the spinal cord protein levels of procaspase-9 (47 kDa) and cleavage products (37 and 35 kDa) and relative
density following western immunoblotting on days 3 (a and b, resp.) and 7 (c and d, resp.) after CCI. Administration of ceftriaxone (Cef
200mg/kg, i.p.) started when CCI was induced and continued for 7 successive days.The semiquantitative analysis of protein levels was carried
out by the “Gel Doc 2000 UV System” (Alliance 4.7). Each lane was loaded with 100𝜇g of proteins. 𝛽-Actin is the loading protein control.
Data were mean ± SEM (𝑛 = 3/group). One-way ANOVA followed by Tukey’s post hoc test was used for multiple comparisons. ##𝑃 < 0.01
difference between CCI-NS and sham/naive animals. ∗𝑃 < 0.05, ∗∗𝑃 < 0.05 CCI-Cef versus NS-CCI group (control).
3.4. Malondialdehyde Levels. As indicated in Table 1, at day 3
after operation, there was a significant increase in the spinal
cord MDA levels following CCI in animals that received
normal saline as compared with naı¨ve (𝑃 < 0.05) and sham-
operated groups (𝑃 < 0.01). Levels of MDA remained high
on day 7 after CCI. Seven days of treatment with ceftriaxone
resulted in a significant reduction in the free radical-mediated
lipid peroxidation on days 3 and 7 as indicated by the
decreased levels of MDA compared to CCI saline-treated
group (𝑃 < 0.05).
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Figure 3: Effect of ceftriaxone on the spinal cord protein levels of procaspase-3 (37 kDa) and cleavage product (17 kDa) and relative density
following western immunoblotting on days 3 (a and b, resp.) and 7 (c and d, resp.) after CCI. Administration of ceftriaxone (Cef 200mg/kg,
i.p.) started when CCI was induced and continued for 7 successive days.The semiquantitative analysis of protein levels was carried out by the
“Gel Doc 2000 UV System” (Alliance 4.7). Each lane was loaded with 100𝜇g of proteins. 𝛽-Actin is the loading protein control. Data were
mean ± SEM (𝑛 = 3/group). One-way ANOVA followed by Tukey’s post hoc test was used for multiple comparisons. #𝑃 < 0.05 difference
between CCI-NS and sham/naive animals. ∗𝑃 < 0.05 CCI-Cef versus NS-CCI group (control).
3.5. Glutathione Levels. After 7 days of CCI, GSH levels were
significantly decreased in the spinal cord of animals receiving
normal saline, in relation to that of the sham and na¨ıve groups
(𝑃 < 0.01). Ceftriaxone significantly increased antioxidant
power by a significant increase in the levels of GSH on day 7
in the spinal cord of CCI animals (𝑃 < 0.05) (Table 1).
4. Discussion
Antinociceptive effects of ceftriaxone have been shown in
our previous study [14]. GLT1 upregulation and activation
are assumed to be the main mechanisms of neuroprotective
effects of ceftriaxone in various experimental models includ-
ing neuropathic pain [7, 11, 12, 15]. In the present study, the
time course alterations in apoptosis markers (Bax : Bcl2), as
well as caspases 3 and 9, were evaluated on days 3 and 7
after CCI. We also measured oxidative markers, MDA and
GSH, in the lumbar spinal cord of animals on the 3rd and
7th days after CCI. On day 3, after operation, CCI induced
elevated level of Bax protein, while a slight decrease was
observed in the Bcl2 protein level. Therefore, a significant
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Table 1:The effect of intraperitoneal ceftriaxone (200mg/kg) on the levels of malondialdehyde (MDA) and glutathione (GSH) in the lumbar
spinal cord of 3- and 7-day CCI rats. Animals were treated with ceftriaxone for 7 days and administration started when CCI was induced. Data
are presented as mean ± SEM (𝑛 = 3). One-way ANOVA followed by Tukey’s post hoc test was used for multiple comparisons. ##𝑃 < 0.01,
#
𝑃 < 0.05 difference between CCI-NS and sham/naive animals. ∗𝑃 < 0.05 CCI-Cef group versus NS-CCI group (control).
Control group (normal
saline CCI rats) Sham group
Naive group (intact rats with
daily 200mg/kg ceftriaxone)
Treated group (CCI rats with
daily 200mg/kg ceftriaxone)
MDA (nmol/mg protein)
Day 3 12.9 ± 2.5## 4.3 ± 0.23 4.7 ± 0.23 5.9 ± 1.2∗
Day 7 10.7 ± 2.1# 3 ± 0.16 3.1 ± 0.17 4.5 ± 1.2∗
GSH (nmol/mg protein)
Day 3 37.7 ± 10.4 49 ± 11 41 ± 3.4 42.5 ± 3.8
Day 7 33.5 ± 4.6## 55.2 ± 2.5 48.9 ± 2.3 40.6 ± 2.4∗
elevation was detected in the Bax/Bcl2 ratio in animals
subjected to CCI at this time. Bax is representative apoptotic
protein in the Bcl2 family and responsible for the subsequent
activation of caspases and cell apoptosis. Indeed, the ratio
of Bax to Bcl2 can determine the susceptibility of cells to
cell death. A functional imbalance between proapoptotic
Bax and antiapoptotic Bcl2 has been implicated following
chronic constriction of sciatic nerve in rats [23]. As there
was not a significant difference between apoptotic protein
levels of na¨ıve animals treated with ceftriaxone relative
to those of sham-operated animals, it could be suggested
that ceftriaxone has no direct effect on apoptotic proteins.
However, ceftriaxone reduced Bax and increased Bcl2 levels
in CCI animals and as a result a significant decrease was
detected in the Bax/Bcl2 ratio of spinal cord in the sciatic
nerve CCI rats on postoperative day 3. In this study, we found
a significant induction of cleaved forms of caspases 3 and 9 on
day 3 after CCI followed by a decrease at day 7. In agreement
with this, a recent study byWu et al. showed that treatment of
CCI animals with inhibitor of caspase-3 and siRNA targeting
caspase-3 significantly inhibited the apoptosis of neurons and
the thermal hyperalgesia following sciatic nerve ligation [24].
Joseph and Levine showed that caspase signaling pathway
contributed to the pain induced in two models of painful
peripheral neuropathy [16]. In CCI animals treated with nor-
mal saline, Bax/Bcl2 ratio of spinal cord declined thereafter
on day 7. There were also no detectable cleaved forms of
caspases 3 and 9 in the spinal cord of NS-CCI animals.
Thereafter, there was no difference amongCCI-vehicle, sham,
na¨ıve, and CCI-ceftriaxone treated groups by day 7. Our
data in the present study supports the evidence that, in the
CCI of sciatic nerve, the development of neuropathic pain
may be associated with the activation of apoptosis process
[16, 24]. However, depending on the time point of study,
there are differences in pattern of apoptosis occurrence.
As the antiapoptotic protein, Bcl2, increased in the control
group, it seems that as a modulatory mechanism apoptotic
process via mitochondria is limited to the first few days
after nerve injury which is consistent with some studies.
An early apoptosis (2-3 days after CCI) occurred transiently
by the increased ratio of Bax/Bcl2 genes in a study by de
Novellis and collogues. An inversed pattern of Bcl2 family
genes expression was detected at later stages [3]. Thus, there
was a significant lowering in Bax/Bcl2 and Bcl-Xs/Bcl-xL
ratios over time as a consequence of increased expression
of antiapoptotic Bcl2 and Bcl-xL. In a study by Costa et al.,
increase in the ratio between pro- and antiapoptotic gene
Bax/Bcl2 expression in the spinal cord of neuropathic rats
was also limited to the first few days following nerve injury
[25]. Siniscalco and coworkers revealed that the levels of Bax,
apoptotic protease-activating factor-1 (apaf-1), nestin, GFAP,
and caspase-7mRNA increased in the dorsal horn spinal cord
by 3 days after CCI. At 7 days after CCI, only overexpression
of Bcl2, nestin, and GFAP mRNA was observed [26]. In a
study by Rezende et al., expression of Bax gene and Bax
protein increased, while the expression of Bcl2 RNA was
decreased in 5 days sciatic nerve transection rats [27].
Despite the decreased levels of proapoptotic proteins after
7 days of CCI, elevated levels of MDA and decreased levels
of GSH remained in the spinal cord of 7-day CCI rats,
which was consistent with the development of behavioral
data in our previous study. Consequently, it seems that other
mechanisms other than apoptosis through mitochondrial
pathways at this time contribute to the behavioral parameters
of neuropathic pain. Moreover, the important contributory
role of oxidative stress is supported in the pathogenesis of
neuropathic pain [6, 28]. However, it might be possible that
apoptosis process again is activated after the time course of
our study. Hence, taking more stage samples such as days 10
or 14 may help to better characterize time course of apoptotic
factors activation. Treatment with ceftriaxone in CCI rats
decreased spinal cord levels of MDA and increased contents
of GSH, on days 3 and 7 after CCI, as comparedwith the vehi-
cle treated control group. It has been shown that increased
levels of glutamatewith the prevention of cysteine uptake into
the cells lead to cysteine and glutathione depletion from cells
which is subsequently accompanied by an increase in reactive
oxygen species (ROS). On the other hand, depletion of GSH
is correlated with glutamate excitotoxicity [29]. Glutamate
transporters contribute not only to the prevention of toxicity
caused by glutamate but also to the stimulation of cysteine
uptake through the cysteine/glutamate antiporter and also
generation of GSH by providing intracellular glutamate [30].
Although the exact mechanism of antioxidant and anti-
apoptotic effects of ceftriaxonewas not evaluated in our study,
it seems that ceftriaxone through different mechanisms and
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pathways shows neuroprotective effects. For example, in a
study by Sari et al., ceftriaxone reduced ethanol consumption
in an animal model of alcohol abuse; however, only the
highest doses increased the GLT1 expression. They suggested
that ceftriaxone may have additional pharmacological effects
independent of the activation and/or upregulation of GLT1
[31]. An in vitro study showed that ceftriaxone treatment
increased GSH and glutamate/cystine-antiporter levels and
suggested that neuroprotective effects of ceftriaxone might
relate more strongly to activation of the antioxidant defense
system [32]. Chu et al. revealed that ceftriaxone protected
against focal cerebral ischemia by increasing the levels of
GLT1 as well as reducing the levels of proinflammatory
cytokines (tumor necrosis factor),matrixmetalloproteinase 9
(MMP-9), and activated caspase-9 [33]. In a study by Ramos
and coworkers, ceftriaxone inhibited astrocyte activation by
downregulation of GFAP as well as upregulation of GLT1
expression, inCCI animals [34].MacAluso et al. reported that
a single dose of ceftriaxone but not cefazolin, a structurally
similar cephalosporin antibiotic to ceftriaxone, produced
analgesia in patients with painful neuropathies and mouse
models of inflammatory or postsurgical pain [35]. It has
previously been demonstrated that increased expression of
GLT1 by ceftriaxone occurs after a few days [8, 11].
5. Conclusion
Taken together, ceftriaxone as a GLT1 upregulator/activator
could concomitantly prevent lipid peroxidation and oxida-
tive stress-mediated apoptosis and activate the antioxidant
defense system with restoring the levels of GSH. Ceftriaxone
andnewdrugs that act in a similarmanner butwithout antibi-
otic properties could be a suitable approach for ameliorating
and potentially preventing a wide range of neurodegenerative
diseases caused by glutamate excitotoxicity.
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